search

Active clinical trials for "Prostatic Neoplasms"

Results 261-270 of 5298

Androgen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy

Prostate Cancer

The overall aim of this project is to test the hypothesis that the addition of ADT to metastasis-directed radiotherapy (MDRT) in well-selected PCa patients with oligo-metastatic disease prolongs the metastases progression-free survival (MPFS) compared to MDRT alone.

Recruiting21 enrollment criteria

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy...

Urologic CancerBiochemical Recurrence of Malignant Neoplasm of Prostate

To evaluate the efficacy and safety of a pembrolizumab therapy of pembrolizumab in combination with standard salvage radiation therapy (SRT) in patients with biochemical recurrence (BCR) of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP).

Recruiting29 enrollment criteria

Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant...

Metastatic Castration-resistant Prostate CancerAdenocarcinoma of the Prostate

The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.

Recruiting50 enrollment criteria

Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive...

Prostate CancerRadiotherapy Side Effect1 more

de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.

Recruiting9 enrollment criteria

5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)...

Oligometastatic Prostate Cancer

We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.

Recruiting19 enrollment criteria

A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy

Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or locally advanced prostate cancer using pathologic complete response (pCR) rate and metastasis-free survival (MFS).

Recruiting12 enrollment criteria

Functional Image-Guided Carbon Ion Irradiation With Simultaneous Integrated Boost for Prostate Cancer...

Localized Prostate Cancer

This is a phase II randomized controlled clinical trial to assess the toxicities and clinical efficacy of prostate specific membrane antigen (PSMA) positron emission tomography / computed tomography (PET/CT) and multi- parameter Magnetic Resonance Imaging (MRI) guided simultaneous integrated boost for prostate cancer.

Recruiting16 enrollment criteria

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate...

Oligometastatic Prostate CarcinomaProstate Adenocarcinoma1 more

This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of the body (oligometastatic). Testosterone can cause the growth of prostate cancer cells. Relugolix lowers the amount of testosterone made by the body. This may help stop the growth of tumor cells that need testosterone to grow. Giving relugolix with radiation therapy may help lower the chance of prostate cancer growing or spreading.

Recruiting56 enrollment criteria

A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate...

Prostate CancerProstate Adenocarcinoma

Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi-centered randomized control trial. This study will determine whether the TULSA procedure is as effective and more safe compared to radical prostatectomy.

Recruiting17 enrollment criteria

Robot-Assisted Radical Prostatectomy With or Without Vesicopexy in Patients With Prostate Cancer...

Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v87 more

This phase III trial compares the effects of robot-assisted radical prostatectomy (RARP) with or without vesicopexy on urinary continence (a person's ability to control their bladder) and quality of life in patients with cancer of the prostate. RARP is the most adopted surgical approach for treatment of prostate cancer that has not spread to other places in the body (non-metastatic). Urinary incontinence (inability to control the bladder) is one of the most common complications of RARP, impacting patients' quality of life and psychological well-being. Different techniques have been proposed to improve urinary continence following RARP. Vesicopexy is one technique that restores the bladder to its normal position in the body after RARP. This study aims to evaluate whether RARP with vesicopexy may improve urinary continence and quality of life after surgery in prostate cancer patients.

Recruiting10 enrollment criteria
1...262728...530

Need Help? Contact our team!


We'll reach out to this number within 24 hrs